The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers

PURPOSE: Deutetrabenazine is a deuterated form of tetrabenazine with a confirmed lower rate of CYP2D6 metabolism of the active metabolites, α- and β-HTBZ. In this study, we assessed the effect of paroxetine, a potent CYP2D6 inhibitor, on the pharmacokinetics and safety of deutetrabenazine and its me...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, F., Stamler, D., Bradbury, M. J., Loupe, P. S., Gordon, M. F., Rabinovich-Guilatt, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724172/
https://www.ncbi.nlm.nih.gov/pubmed/34491372
http://dx.doi.org/10.1007/s00228-021-03202-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724172/
https://www.ncbi.nlm.nih.gov/pubmed/34491372
http://dx.doi.org/10.1007/s00228-021-03202-0

Ejemplares similares